基本信息
浏览量:378
职业迁徙
个人简介
An accomplished molecular oncologist and translational thought leader, Dr. Khuri's clinical expertise and research are focused on the development of molecular, prognostic, therapeutic, and chemopreventive approaches to improve the standard of care for patients with lung and aerodigestive cancers. He has conducted seminal research on oncolytic viral therapy, developed approaches to integrate molecularly targeted therapies by combining signal transduction inhibitors with chemotherapy, pioneered novel induction and window of opportunity trials, and led major cooperative group chemoprevention efforts for these cancers. His laboratory group investigates mechanisms of action of signal transduction inhibitors in lung and aerodigestive track cancers based on the selective activation of certain signaling networks.
Dr. Khuri's ability to build teams with the singular vision of improving outcomes for cancer patients helped develop Winship into a premier translational research engine. Dr. Khuri led the recruitment of over 90 faculty including 60 clinical investigators to Emory University, helping oversee an increase in adult cancer patients placed on trial annually from 143 in 2002 to over 650 in 2014, and paving the way for NCI designation for the Winship. Along with Haian Fu, PhD, Khuri founded the Winship's Cancer Drug Discovery, Development, and Delivery Program. Working closely with Drs. Fu, Shi-Yong Sun, and colleagues, Dr. Khuri led a programmatic approach to pioneer novel therapeutic approaches to this disease. This work has led to a Lung P01 (FR Khuri, PI, H Fu, co-PI), head and neck cancer SPORE (Dong M. Shin, PI; Khuri, co-PI), U01 in Chemical Genomics (H Fu, PI, FR Khuri, co-PI), and multiple spin-off R01s, significantly expanding its impact. In May 2015, his team submitted a new, paradigm-shifting P01 entitled “Targeting LKB1-associated tumor vulnerability in lung cancer," an application that uses state of the art genomics and systems biology approaches to interrogate several major survival nodes in lung cancer, developing targeted approaches to block multiple key nodes of critical lung cancer survival signaling networks.
Dr. Khuri's ability to build teams with the singular vision of improving outcomes for cancer patients helped develop Winship into a premier translational research engine. Dr. Khuri led the recruitment of over 90 faculty including 60 clinical investigators to Emory University, helping oversee an increase in adult cancer patients placed on trial annually from 143 in 2002 to over 650 in 2014, and paving the way for NCI designation for the Winship. Along with Haian Fu, PhD, Khuri founded the Winship's Cancer Drug Discovery, Development, and Delivery Program. Working closely with Drs. Fu, Shi-Yong Sun, and colleagues, Dr. Khuri led a programmatic approach to pioneer novel therapeutic approaches to this disease. This work has led to a Lung P01 (FR Khuri, PI, H Fu, co-PI), head and neck cancer SPORE (Dong M. Shin, PI; Khuri, co-PI), U01 in Chemical Genomics (H Fu, PI, FR Khuri, co-PI), and multiple spin-off R01s, significantly expanding its impact. In May 2015, his team submitted a new, paradigm-shifting P01 entitled “Targeting LKB1-associated tumor vulnerability in lung cancer," an application that uses state of the art genomics and systems biology approaches to interrogate several major survival nodes in lung cancer, developing targeted approaches to block multiple key nodes of critical lung cancer survival signaling networks.
研究兴趣
论文共 876 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Eric Bernicker, Steve D. Averbuch,Stephen Edge, Jasmine Kamboj,Fadlo R. Khuri,Jennifer Young Pierce,Joan Schiller, Bhawna Sirohi, Alexandra Thomas,Allyn Moushey,Jonathan Phillips, Carolyn Hendricks
JCO ONCOLOGY PRACTICEno. 2 (2024): 178-186
加载更多
作者统计
#Papers: 874
#Citation: 43784
H-Index: 105
G-Index: 187
Sociability: 8
Diversity: 0
Activity: 2
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn